These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1552104)

  • 1. The rt-PA versus streptokinase controversy--III.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1992 Apr; 19(5):1119-20. PubMed ID: 1552104
    [No Abstract]   [Full Text] [Related]  

  • 2. The rt-PA versus streptokinase. Controversy--II.
    Braunwald E; Knatterud G; Passamani E
    J Am Coll Cardiol; 1992 Apr; 19(5):1116-9. PubMed ID: 1552103
    [No Abstract]   [Full Text] [Related]  

  • 3. The rt-PA versus streptokinase controversy--IV.
    Swan HJ
    J Am Coll Cardiol; 1992 Apr; 19(5):1120. PubMed ID: 1552105
    [No Abstract]   [Full Text] [Related]  

  • 4. The rt-PA versus streptokinase. Controversy--I.
    Lenfant C
    J Am Coll Cardiol; 1992 Apr; 19(5):1116. PubMed ID: 1348064
    [No Abstract]   [Full Text] [Related]  

  • 5. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streptokinase versus recombinant tissue-type plasminogen activator.
    Guharoy SR
    DICP; 1991 Nov; 25(11):1271-2. PubMed ID: 1763549
    [No Abstract]   [Full Text] [Related]  

  • 7. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
    Collen D
    Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
    Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
    Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the clinical laboratory in monitoring fibrinolytic therapy of acute myocardial infarction.
    Bovill E; Triplett D; Stump D
    Hematol Pathol; 1990; 4(2):61-6. PubMed ID: 2115512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis after myocardial infarction.
    Verstraete M
    Lancet; 1988 Apr; 1(8588):763. PubMed ID: 2895284
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of streptokinase and tissue plasminogen activator on left ventricular function.
    White HD
    Adv Exp Med Biol; 1990; 281():383-7. PubMed ID: 2129375
    [No Abstract]   [Full Text] [Related]  

  • 16. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 17. Altered rheological properties of blood following administrations of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction.
    Jan KM; Powers E; Reinhart W; Berke A; Nichols A; Watson R; Reison D; Schwartz A; Chien S
    Adv Exp Med Biol; 1990; 281():409-17. PubMed ID: 2129379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
    Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
    Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue plasminogen activator: why the backlash?
    Topol EJ; Califf RM
    J Am Coll Cardiol; 1989 Jun; 13(7):1477-80. PubMed ID: 2498415
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombolysis in myocardial infarction (TIMI): update 1987.
    Mueller HS
    Klin Wochenschr; 1988; 66 Suppl 12():93-101. PubMed ID: 3126350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.